logo.jpg
Helsinn appoints Mary Lynne Hedley to Board of Directors
April 29, 2021 03:00 ET | Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
logo.jpg
Helsinn appoints Mary Lynne Hedley to Board of Directors
April 29, 2021 03:00 ET | Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
logo.jpg
Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan
April 21, 2021 02:30 ET | Helsinn Healthcare S.A.
Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan Lugano, Switzerland, April 21, 2021 – Helsinn, a Swiss pharmaceutical group focused on building...
logo.jpg
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV
April 13, 2021 08:00 ET | Helsinn Healthcare S.A.
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV Lugano, Switzerland, April 13, 2021 – Helsinn,...
logo.jpg
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
March 31, 2021 07:30 ET | Helsinn Healthcare S.A.
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology BridgeBio, through its Affiliate QED...
logo.jpg
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
March 18, 2021 08:30 ET | Helsinn Healthcare S.A.
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
logo.jpg
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
February 18, 2021 08:00 ET | Helsinn Healthcare S.A.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
logo.jpg
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
January 22, 2021 01:39 ET | Helsinn Healthcare S.A.
     ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Not intended for US media ...
logo.jpg
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
January 12, 2021 03:30 ET | Helsinn Healthcare S.A.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss...
logo.jpg
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor
December 07, 2020 08:30 ET | Helsinn Healthcare S.A.
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor   Lugano,...